BNR – Burning Rock Biotech Ltd 燃石医学

Burning Rock Biotech Ltd(燃石医学有限责任公司)专注于为肿瘤精准医疗提供具有临床价值的二代测序(next generation sequencing, NGS)服务,公司业务及研发方向主要覆盖:(1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过18.5万例,在中国拥有最高的市场份额;(2)基于NGS的癌症早检,目前已经进入临床验证阶段。燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。公司于2014年3月10日在开曼群岛注册成立.

中文介绍: https://xueqiu.com/S/BNR

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.

英文介绍: https://www.morningstar.com/stocks/xnas/bnr/quote

主题测试文章,只做测试使用。发布者:star,转转请注明出处:http://wallstreetgm.com/bnr-burning-rock-biotech-ltd-%e7%87%83%e7%9f%b3%e5%8c%bb%e5%ad%a6/

发表评论

您的电子邮箱地址不会被公开。 必填项已用*标注